EGFR and lung adenocarcinoma: For example, small molecule tyrosine kinase inhibitors (TKIs) were proven to be effective for patients with advanced lung adenocarcinoma who harbor somatic mutation of epidermal growth factor receptor (EGFR), as well as the rearrangement of echinoderm microtubule-associated protein-like 4 (EML4) with anaplastic lymphoma (ALK) (18–22).